Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stomach cancer surgery may get simpler: omentum preservation under study

NCT ID NCT05180864

Disease control Sponsor: Amsterdam UMC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares two surgical approaches for stomach cancer: removing the entire omentum (a fatty layer in the abdomen) versus preserving it. The omentum helps fight infections and prevent bowel blockages. Researchers want to see if keeping it leads to fewer complications without affecting survival. About 654 adults with resectable stomach cancer will be randomly assigned to one of the two procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
gastrectomy (surgery to remove part or all of the stomach)
What this could lead to
If successful, this could show that preserving the omentum during stomach cancer surgery is just as effective as removing it, while reducing complications like infections and bowel blockages.
What could go wrong
This is a non-inferiority trial, meaning it aims to prove that preserving the omentum is not worse than removing it. However, it is still recruiting and results are not yet available, so there is no guarantee of benefit or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 654 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Primary resectable gastric adenocarcinoma, clinical stage T1-4aN0-3M0 * ASA 1-3 (able to undergo surgery) * Scheduled for open or minimally invasive (sub)total gastrectomy with modified D2-lymphadenectomy, with or without perioperative chemotherapy * Age above 18 * Able to complete questionnaires in Dutch, English or Italian * Written informed consent * Esophageal invasion \< 2 cm defined from the upper margin of the gastric rugae as determined by endoscopy Exclusion Criteria: * Gastric cancer clinically staged as T1N0 * Locally advanced gastric cancer requiring multi-visceral resection * Pregnancy * Previous malignancy (excluding non-melanoma skin cancer, pancreatic neuroendocrine tumor (pNET) \<2cm, and gastrointestinal stromal tumor (GIST) \<2cm), unless no evidence of disease and diagnosed more than three years before diagnosis of gastric cancer, or with a life expectancy of more than five years from date of inclusion * Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator * Previous gastric or omental surgery, with the exclusion of a gastric perforation Indication for thoracotomy/thoracoscopy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stomach neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    16 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam UMC

    RECRUITING

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Antoni van Leeuwenhoek

    NOT_YET_RECRUITING

    Amsterdam, Netherlands

  • Azienda Ospedaliera Universitaria

    NOT_YET_RECRUITING

    Siena, Italy

  • Catharina Ziekenhuis

    RECRUITING

    Eindhoven, Netherlands

  • Elisabeth Tweesteden ziekenhuis

    NOT_YET_RECRUITING

    Tilburg, Netherlands

  • Erasmus Medisch Centrum

    NOT_YET_RECRUITING

    Rotterdam, Netherlands

  • Gelre ziekenhuis

    NOT_YET_RECRUITING

    Apeldoorn, Netherlands

  • Leids Universitair Medisch Centrum

    NOT_YET_RECRUITING

    Leiden, Netherlands

  • Medisch Centrum Leeuwarden

    NOT_YET_RECRUITING

    Leeuwarden, Netherlands

  • Oxford University Hospitals

    NOT_YET_RECRUITING

    Oxford, United Kingdom

  • Rijnstate ziekenhuis

    NOT_YET_RECRUITING

    Arnhem, Netherlands

  • Universitair Medisch Centrum Utrecht

    NOT_YET_RECRUITING

    Utrecht, Netherlands

  • Universitait Medisch Centrum Groningen

    NOT_YET_RECRUITING

    Groningen, Netherlands

  • University Medical Center of the Johannes Gutenberg University

    NOT_YET_RECRUITING

    Mainz, Germany

  • Ziekenhuis Groep Twente

    NOT_YET_RECRUITING

    Almelo, Netherlands

  • Zuyderland ziekenhuis

    NOT_YET_RECRUITING

    Heerlen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.